Aldeyra Therapeutics Inc. (NASDAQ: ALDX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT ALDEYRA THERAPEUTICS INC.

Aldeyra Therapeutics Inc. (NASDAQ: ALDX)
Listen to this Section


$1.66
-0.1050 ( -5.97% ) 442.5K

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Clinical Trial Pipeline Stages


Drug Name Stage
Reproxalap (ADX-102)DetailsRare genetic disease, Rare diseases, Allergic conjunctivitis Phase 3
ADX-2191 (methotrexate injection (DHFR inhibitor))DetailsEye disease , Retinitis Pigmentosa Phase 2/3
ADX-629DetailsSjögren-Larsson Syndrome Phase 2
ADX-629DetailsAlcoholic hepatitis, Liver disease Phase 2
ADX-629DetailsChronic cough Failed
ADX-629DetailsIdiopathic Nephrotic Syndrome Failed
ADX-629DetailsAtopic dermatitis Phase 2a
ADX-246DetailsAtopic dermatitis, Skin disease/disorder Phase 1/2
ADX-248DetailsAge-related macular degeneration, Geographic atrophy Phase 1/2
ADX-248DetailsAtopic dermatitis, Skin disease/disorder Phase 1
ADX-2191DetailsEye disease , Retinitis Pigmentosa Phase 2/3
ADX-2191DetailsEye disease , Proliferative vitreoretinopathy, Rare diseases, Primary Vitreoretinal Lymphoma Failed

Market Data


Open $1.66
Previous Close $1.76
Volume 442.5K
Market Cap $112.20M
Day Range $1.66 - $1.85
52 Week Range $1.07 - $6.18
Shares Outstanding 60.32M
Change % -5.97%
Net Change ▼ -0.1050
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2014
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -2,828,883.00

Date Type Amount Purchased Purchaser
2024-06-06 Sale -40282.00 Phillips Gary M.
2024-04-08 Buy 140281.00 PERCEPTIVE ADVISORS LLC
2024-04-03 Buy 8374.00 PERCEPTIVE ADVISORS LLC
2024-03-12 Sale -13201.00 Greenberg Bruce
2024-03-12 Sale -18231.00 Machatha Stephen
2024-03-12 Sale -97914.00 Brady Todd C
2023-10-18 Sale -2450000.00 PERCEPTIVE ADVISORS LLC
2023-09-11 Sale -192084.00 Brady Todd C
2023-09-11 Sale -5437.00 Phillips Gary M.
2023-08-24 Sale -9604.00 Walker Neal

SEC Filings


Form Type Description Pages Date
8-k 8K-related 9 Apr 01, 2026
4 Insider transactions 1 Mar 31, 2026
schedule Other 1 Mar 26, 2026
4 Insider transactions 1 Mar 20, 2026
4 Insider transactions 1 Mar 19, 2026
8-k 8K-related 10 Mar 17, 2026
s-8 Registration statements 17 Feb 27, 2026
10-k Annual reports 93 Feb 27, 2026
schedule Other 1 Feb 17, 2026
8-k 8K-related 12 Dec 31, 2025

Latest News


× Before browsing our site, please accept our cookies policy